Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Benzinga06-08 21:26

The partnership aims to enhance treatment options for patients with B-cell malignancies, a sector projected to grow significantly, with the combined market expected to reach $41 billion by 2031. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641320487?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/06/08/Acute-Myeloid-Leukemia-Is-A-Subtype-Of-B.jpeg","is_english":true,"pubTime":"2026-06-08 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641320487","market":"nz","top_or_hot":-1,"title":"Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market","media":"Benzinga","content":"<div>\n<p>The partnership aims to enhance treatment options for patients with B-cell malignancies, a sector projected to grow significantly, with the combined market expected to reach $41 billion by 2031.\nThe ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/53056750/nurix-therapeutics-gains-ground-as-roche-partnership-targets-growing-b-cell-blood-cancer-market\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-08 21:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/06/53056750/nurix-therapeutics-gains-ground-as-roche-partnership-targets-growing-b-cell-blood-cancer-market><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The partnership aims to enhance treatment options for patients with B-cell malignancies, a sector projected to grow significantly, with the combined market expected to reach $41 billion by 2031.\nThe ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/53056750/nurix-therapeutics-gains-ground-as-roche-partnership-targets-growing-b-cell-blood-cancer-market\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMA","symbol_name":"Smartstop Self Storage REIT Inc","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/06/53056750/nurix-therapeutics-gains-ground-as-roche-partnership-targets-growing-b-cell-blood-cancer-market","article_id":"2641320487","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/06/08/Acute-Myeloid-Leukemia-Is-A-Subtype-Of-B.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/06/53056750/nurix-therapeutics-gains-ground-as-roche-partnership-targets-growing-b-cell-blood-cancer-market","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641320487","pubTimestamp":1780925160,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMA":"Smartstop Self Storage REIT Inc","BK4139":"生物科技","BK4217":"自存仓储房地产信托","NRIX":"Nurix Therapeutics"},"translate_title":"罗氏合作瞄准不断增长的B细胞血癌市场，Nurix Therapeutics取得进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMA":1,"NRIX":1.5},"content_text":"The partnership aims to enhance treatment options for patients with B-cell malignancies, a sector projected to grow significantly, with the combined market expected to reach $41 billion by 2031.\nThe collaboration with Roche will focus on bexobrutideg, which is set to enter Phase 3 clinical trials for treating chronic lymphocytic leukemia (CLL) in the summer of 2026.\nThe partnership is seen as a strategic move to leverage Roche’s strengths in hematology and expand Nurix’s pipeline into immunology and neurology.\nUnder the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory, and sales milestones for a potential total deal value of up to $2.3 billion.\nDevelopment costs will be shared 40% by Nurix and 60% by Roche. The parties will equally split the profits and losses from U.S. commercialization.\nNurix and Roche will co-commercialize bexobrutide in the U.S. across all indications.\nOutside the U.S., Roche will be responsible for commercialization, with Nurix receiving royalties ranging from the low to high teens.\nCurrently, Nurix Therapeutics is trading at $22.28, significantly above its 20-day simple moving average (SMA) of $16.42, indicating strong bullish momentum. \nThe stock is also 30.3% above its 20-day SMA, 30.9% above its 50-day SMA, and 45% above its 200-day SMA, suggesting a robust upward trend.\nThe moving average convergence divergence (MACD) is currently below its signal line, indicating that upside momentum may be cooling unless it can reclaim that baseline. This suggests that while the stock is experiencing a strong rally, traders should be cautious of potential pullbacks.\nKey Resistance: $22.50 — a nearby level where rebounds can stall, aligning with the recent swing high and a round-number area. Key Support: $17.50 — a nearby level where buyers previously stepped in, providing a potential safety net for the stock.\nNRIX Stock Price Activity: Nurix Therapeutics shares were up 51.23% at $22.14 during premarket trading on Monday, according to Benzinga Pro data.\nImage via Shutterstock/ Yomal2233\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641320487","isCrawlerRequest":true}